337 related articles for article (PubMed ID: 36163119)
21. Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer.
Wang GP; Qi ZH; Chen FP
Med Hypotheses; 2008; 70(1):122-7. PubMed ID: 17566667
[TBL] [Abstract][Full Text] [Related]
22. Cellular and Molecular State of Myeloid Leukemia Stem Cells.
Xie X; Feng M; Wang Q; Wang J; Yin R; Li Y; Zhang H
Adv Exp Med Biol; 2019; 1143():41-57. PubMed ID: 31338814
[TBL] [Abstract][Full Text] [Related]
23. Leukemia Stem Cells Microenvironment.
Tabe Y; Konopleva M
Adv Exp Med Biol; 2017; 1041():19-32. PubMed ID: 29204827
[TBL] [Abstract][Full Text] [Related]
24. Regulation of hematopoietic and leukemic stem cells by the immune system.
Riether C; Schürch CM; Ochsenbein AF
Cell Death Differ; 2015 Feb; 22(2):187-98. PubMed ID: 24992931
[TBL] [Abstract][Full Text] [Related]
25. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
26. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
27. Understanding of leukemic stem cells and their clinical implications.
Wang X; Huang S; Chen JL
Mol Cancer; 2017 Jan; 16(1):2. PubMed ID: 28137304
[TBL] [Abstract][Full Text] [Related]
28. Leukemic stem cells: identification and clinical application.
Hanekamp D; Cloos J; Schuurhuis GJ
Int J Hematol; 2017 May; 105(5):549-557. PubMed ID: 28357569
[TBL] [Abstract][Full Text] [Related]
29. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
Velasco-Hernandez T; Trincado JL; Vinyoles M; Closa A; Martínez-Moreno A; Gutiérrez-Agüera F; Molina O; Rodríguez-Cortez VC; Ximeno-Parpal P; Fernández-Fuentes N; Petazzi P; Beneyto-Calabuig S; Velten L; Romecin P; Casquero R; Abollo-Jiménez F; de la Guardia RD; Lorden P; Bataller A; Lapillonne H; Stam RW; Vives S; Torrebadell M; Fuster JL; Bueno C; Sarry JE; Eyras E; Heyn H; Menéndez P
Hemasphere; 2024 Feb; 8(2):e45. PubMed ID: 38435427
[TBL] [Abstract][Full Text] [Related]
30. [Progress in the studies of acute myelogenous leukemia stem cell].
Cui JW; Zhang XM; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558
[TBL] [Abstract][Full Text] [Related]
31. Location First: Targeting Acute Myeloid Leukemia Within Its Niche.
Pievani A; Biondi M; Tomasoni C; Biondi A; Serafini M
J Clin Med; 2020 May; 9(5):. PubMed ID: 32443460
[TBL] [Abstract][Full Text] [Related]
32. [Acute myeloid leukemia stem cells from genomic and immunological perspectives].
Goyama S
Rinsho Ketsueki; 2020; 61(9):1130-1137. PubMed ID: 33162508
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia: therapeutic targeting of stem cells.
Pabon CM; Abbas HA; Konopleva M
Expert Opin Ther Targets; 2022 Jun; 26(6):547-556. PubMed ID: 35634856
[TBL] [Abstract][Full Text] [Related]
34. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
[TBL] [Abstract][Full Text] [Related]
35. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
36. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
[TBL] [Abstract][Full Text] [Related]
37. Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias.
Zhai X; Jiang X
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009388
[TBL] [Abstract][Full Text] [Related]
38. Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
Jin L; Hope KJ; Zhai Q; Smadja-Joffe F; Dick JE
Nat Med; 2006 Oct; 12(10):1167-74. PubMed ID: 16998484
[TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
[TBL] [Abstract][Full Text] [Related]
40. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
